The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.
The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.
The partners will utilize Clearbridge's microfluidics-based rare cell separation technology, with the goal of potentially creating a new product line.
The agreement allows Sysmex to distribute two Streck blood collection tubes for cell-free DNA as part of its medical diagnostics products and services.
The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.
Sysmex's cell-free tumor DNA analysis technology will be used in oncology clinical trials supported by Covance Drug Development, a LabCorp subsidiary.
IndivuTest will offer the Sysmex Inostics OncoBEAM test in Germany, Austria, and Switzerland under an exclusive distribution agreement.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.